{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vericel Corp. Experiences Valuation Adjustment Amidst Unique Market Position and Performance Metrics
Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and price-to-book value of 7.38. Despite a year-to-date return of -36.15%, its performance metrics indicate potential areas for profitability improvement compared to peers.
Is Vericel Corp. overvalued or undervalued?
As of October 17, 2025, Vericel Corp. is considered overvalued with a P/E ratio of 732 and an EV to EBITDA of 517.61, leading to a valuation grade downgrade from attractive to fair, despite recent short-term stock performance outperforming the S&P 500.
Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Landscape
Vericel Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a price-to-book value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers in the industry.
Is Vericel Corp. overvalued or undervalued?
As of October 17, 2025, Vericel Corp. is considered overvalued with a P/E ratio of 732 and has underperformed the S&P 500, returning -35.68% year-to-date compared to the index's 13.30%.
Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Unique Financial Metrics
Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has undergone a valuation adjustment reflecting its financial metrics and market position. With a notably high P/E ratio and distinct financial ratios, the company presents a unique profile amid challenges in the industry, raising questions about its profitability and efficiency.
Is Vericel Corp. overvalued or undervalued?
As of October 3, 2025, Vericel Corp. is considered undervalued with a high P/E ratio of 732 compared to peers, despite underperforming the S&P 500 year-to-date with a return of -40.92%, while showing a positive three-year return of 42.09%.
Vericel Corp. Experiences Valuation Adjustment Amid Unique Market Dynamics and Performance Metrics
Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and a price-to-book value of 7.38. Despite a year-to-date decline, the company shows a notable five-year increase, indicating unique market dynamics and volatility.
Vericel Corp. Hits New 52-Week Low at $29.24 Amidst Declining Performance
Vericel Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,676 million, has a high P/E ratio and faces challenges in profitability, evidenced by a recent net loss.
Is Vericel Corp. overvalued or undervalued?
As of September 19, 2025, Vericel Corp.'s valuation has improved to "very attractive," indicating it may be undervalued despite a high P/E ratio of 732 compared to peers, and while it has underperformed the S&P 500 over the past year, it has shown a positive return of 33.94% over the last three years, suggesting potential for recovery.
Vericel Corp. Experiences Revision in Its Stock Evaluation Amidst Unique Market Metrics
Vericel Corp., a small-cap biotechnology firm, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and a price-to-book value of 7.38. The company's financial metrics indicate a unique market position, yet it shows underperformance compared to peers and the S&P 500 over recent periods.
Is Vericel Corp. overvalued or undervalued?
As of September 19, 2025, Vericel Corp. has improved its valuation grade to very attractive, but it remains overvalued with a P/E ratio of 732 and significantly underperformed the S&P 500, raising concerns about its current pricing relative to industry peers.
Is Vericel Corp. technically bullish or bearish?
As of August 25, 2025, Vericel Corp. is in a bearish trend with weak strength, indicated by bearish signals across multiple time frames, and has underperformed the S&P 500 with a year-to-date return of -42.00%.
Is Vericel Corp. overvalued or undervalued?
As of September 8, 2025, Vericel Corp. is considered overvalued with a valuation grade of fair, reflected by its high P/E ratio of 732 and poor stock performance, including a year-to-date return of -42.00% compared to the S&P 500's 12.22%.
Vericel Corp. Stock Hits Day Low of $29.93 Amid Price Pressure
Vericel Corp. faced notable stock volatility on September 17, 2025, with a significant decline. Over recent periods, the company's performance has lagged behind the S&P 500, reflecting ongoing challenges. Financial metrics reveal low profitability and modest growth, raising concerns about its long-term prospects despite strong institutional support.
Vericel Corp. Stock Plummets to New 52-Week Low of $29.93
Vericel Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year, contrasting with broader market gains. The company, with a market cap of approximately USD 1.68 billion, faces challenges in profitability and has reported a negative net profit recently.
Is Vericel Corp. overvalued or undervalued?
As of June 16, 2025, Vericel Corp. is considered overvalued with a P/E ratio of 732, significantly higher than its peers, and has underperformed the market with a year-to-date return of -23.88%.
Is Vericel Corp. technically bullish or bearish?
As of June 4, 2025, Vericel Corp. exhibits a mildly bearish trend, supported by mixed technical indicators, including a mildly bullish MACD on the weekly chart but bearish signals from Bollinger Bands and moving averages.
Who are in the management team of Vericel Corp.?
As of March 2022, the management team of Vericel Corp. includes Dr. Robert Zerbe (Independent Chairman), Mr. Dominick Colangelo (CEO), and several independent directors: Dr. Steven Gilman, Ms. Heidi Hagen, Mr. Kevin McLaughlin, Mr. Alan Rubino, and Dr. Paul Wotton. This team provides governance and strategic direction for the company.
What does Vericel Corp. do?
Vericel Corporation is a biopharmaceutical company focused on developing therapies for tissue and organ repair. As of March 2025, it reported net sales of $53 million and a net loss of $11 million, with a market cap of approximately $2.09 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
